IMVT-1402 + IMVT-1402 + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Graves' Disease
Conditions
Graves' Disease
Trial Timeline
Jun 19, 2025 → May 1, 2027
NCT ID
NCT07018323About IMVT-1402 + IMVT-1402 + Placebo
IMVT-1402 + IMVT-1402 + Placebo is a phase 2 stage product being developed by Immunovant for Graves' Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07018323. Target conditions include Graves' Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07018323 | Phase 2 | Recruiting |
| NCT06727604 | Phase 2 | Recruiting |
Competing Products
6 competing products in Graves' Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CFZ533 | Novartis | Phase 2 | 52 |
| Rilzabrutinib dose 1 + Rilzabrutinib dose 2 | Sanofi | Phase 2 | 51 |
| RVT-1401 | Immunovant | Phase 2 | 49 |
| IMVT-1402 | Immunovant | Phase 2 | 49 |
| RVT-1401 (Administered via subcutaneous injection) | Immunovant | Phase 2 | 49 |
| IMVT-1402 + IMVT-1402 + Placebo | Immunovant | Phase 2 | 49 |